Brooks Laboratories Ltd. (NSE: BROOKS, BSE: 533543) is a Mumbai, Maharashtra-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹198 Cr, it ranks #2,661 by market cap among the 6,197 Indian listed companies on FinBizNet, and #5 of 10 in Life Sciences Tools and Services. At ₹67.50 (as of 19 Nov 2026), the share price is 37.9% below its 52-week high of ₹108.70 and 86.0% above its 52-week low of ₹36.30. The share price is down 34.2% over one year and up 13.9% over three months.
| Current Price | ₹67.50 |
|---|---|
| Market Cap | ₹198 Cr |
| NSE Symbol | BROOKS |
| BSE Code | 533543 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 7.9 |
| Return on Equity | 22.28% |
| Return on Assets | 2.77% |
| 52-Week Range | ₹36.30 – ₹108.70 |
| 1-Year Price Change | -34.2% |
| 3-Month Price Change | +13.9% |
| Beta (1Y) | 1.07 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.brookslabs.net |
| Revenue | ₹19 Cr |
|---|---|
| Net Profit | ₹68 Cr |
| Net Margin | 351.2% |
| EPS (Basic) | ₹22.95 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Brooks Laboratories Ltd. reported revenue of ₹19 Cr in Q2 FY27, down 17.9% from ₹23 Cr in Q2 FY26 and down 16.2% from ₹23 Cr in Q1 FY27. It posted a net profit of ₹68 Cr for the quarter, against a net profit of ₹8 Cr in Q2 FY26 (up 747.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹17 Cr (Q3 FY26) to ₹26 Cr (Q1 FY26). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹19 Cr | ₹68 Cr | 351.2% |
| Q1 FY27 | ₹23 Cr | −₹2 Cr | −7.8% |
| Q4 FY26 | ₹20 Cr | ₹2 Cr | 7.5% |
| Q3 FY26 | ₹17 Cr | ₹6 Cr | 33.2% |
| Q2 FY26 | ₹23 Cr | ₹8 Cr | 34.0% |
| Q1 FY26 | ₹26 Cr | ₹10 Cr | 37.6% |
| Q4 FY25 | ₹23 Cr | −₹1 Cr | −6.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 52.62% of Brooks Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 53.1% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and
1. Pharmaceuticals-This segment is engaged in manufacturing various pharmaceutical formulations.
1. Trading-3.3% 2. Manufacturing-96.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,840 Cr | 40.2 | 13.94% | ₹1,122 Cr | +26.1% |
| Suven Life Sciences Ltd. | ₹7,951 Cr | n/m | -78.80% | ₹1 Cr | +51.8% |
| Vimta Labs Ltd | ₹2,259 Cr | 29.5 | 18.55% | ₹112 Cr | -26.8% |
| Tarsons Products Limited | ₹1,730 Cr | 114.9 | 2.26% | ₹124 Cr | +25.7% |
| Brooks Laboratories Ltd. | ₹198 Cr | 7.9 | 22.28% | ₹19 Cr | -34.2% |
| Bilcare Ltd. | ₹194 Cr | 108.3 | -5.21% | — | — |
| Jeevan Scientific Technology Ltd | ₹176 Cr | 129.4 | 1.68% | — | +42.3% |
| Vivo Bio Tech Ltd. | ₹37 Cr | n/m | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹26 Cr | n/m | -68.79% | — | -45.3% |
Listed by market capitalisation. Ratios are shown for context only.
Brooks Laboratories Ltd. is trading at ₹67.50, with a market capitalisation of ₹198 Cr.
Brooks Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Brooks Laboratories Ltd. has a P/E of 7.9 and a return on equity of 22.28%.
Brooks Laboratories Ltd. is listed on the NSE under the symbol BROOKS and on the BSE under the scrip code 533543.
Brooks Laboratories Ltd.'s share price is down 34.2% over one year and up 13.9% over three months. Its 52-week range is ₹36.30 to ₹108.70.
In Q2 FY27, Brooks Laboratories Ltd. reported revenue of ₹19 Cr and net profit of ₹68 Cr, with basic EPS of ₹22.95 (consolidated, parsed from the company's exchange filing).
Brooks Laboratories Ltd. reported revenue of ₹19 Cr in Q2 FY27, down 17.9% from ₹23 Cr in Q2 FY26 and down 16.2% from ₹23 Cr in Q1 FY27.
Promoters held 52.62% of Brooks Laboratories Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.